rezpegaldesleukin
rezpegaldesleukin: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NEKTAR THERAPEUTICS (NKTR) | Phase 2 |
FDA Decisions
FDA_MeetingFDA alignment to evaluate 24 µg/kg Q2W for a 24-week induction with co-primary endpoints EASI-75 and an IGA-related endpoint in two planned Phase 3 registrational trials.(NKTR)
Frequently asked questions
Who is developing rezpegaldesleukin?
rezpegaldesleukin is being developed by NEKTAR THERAPEUTICS.
What is rezpegaldesleukin's latest FDA decision?
The most recent tracked FDA decision for rezpegaldesleukin is FDA_Meeting for FDA alignment to evaluate 24 µg/kg Q2W for a 24-week induction with co-primary endpoints EASI-75 and an IGA-related endpoint in two planned Phase 3 registrational trials..
Get deeper analysis on rezpegaldesleukin
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis